Genflow Biosciences (GENF) RNS Announcements

Add to Alert list
Date Time Source Announcement
19 Jul 2022 07:00 AM
RNS
Company Share Purchase by CEO
29 Jun 2022 07:03 AM
RNS
Board Changes
27 Jun 2022 07:00 AM
RNS
New Research Agreement
14 Jun 2022 11:04 AM
RNS
Results of AGM
26 May 2022 04:40 PM
RNS
Second Price Monitoring Extn
26 May 2022 04:35 PM
RNS
Price Monitoring Extension
26 May 2022 02:05 PM
RNS
Second Price Monitoring Extn
26 May 2022 02:00 PM
RNS
Price Monitoring Extension
26 May 2022 11:05 AM
RNS
Second Price Monitoring Extn
26 May 2022 11:00 AM
RNS
Price Monitoring Extension
25 May 2022 08:27 AM
RNS
International patent application
20 May 2022 07:05 AM
RNS
Notice of Annual General Meeting
16 May 2022 07:15 AM
RNS
Company Update
03 May 2022 07:00 AM
RNS
Collaborative Research Agreement with Organips
29 Apr 2022 07:00 AM
RNS
Posting of Annual Report
25 Apr 2022 07:00 AM
RNS
Genflow to Present at LLWC 2022
29 Mar 2022 07:15 AM
RNS
New Research Collaboration
16 Mar 2022 07:15 AM
RNS
Non-Dilutive Grant Research Award
18 Jan 2022 01:28 PM
RNS
Notification of Major Holdings
17 Jan 2022 07:00 AM
RNS
First Day of Dealings

Genflow Biosciences Plc is a UK-based biotechnology company focused on developing gene therapies to combat aging and age-related diseases in humans and dogs. They have R&D facilities in Belgium and a U.S. office in Cambridge, MA. The company's lead compound, GF-1002, utilizes a centenarian variant of the SIRT6 gene to potentially halt or slow the aging process.

Genflow share price launched at 12p in 2022.

UK 100

Latest directors dealings